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Abstract
Background: Familial hypercholesterolemia (FH) is an autosomal codominant disorder caused by mutations in the low-
density lipoprotein receptor (LDLR) gene. Homozygous FH patients (hoFH) have severe hypercholesterolemia leading to life
threatening atherosclerosis in childhood and adolescence. Mice with germ line interruptions in the Ldlr and Apobec1 genes
(Ldlr
2/2Apobec1
2/2) simulate metabolic and clinical aspects of hoFH, including atherogenesis on a chow diet.
Methods/Principal Findings: In this study, vectors based on adeno-associated virus 8 (AAV8) were used to deliver the gene
for mouse Ldlr (mLDLR) to the livers of Ldlr
2/2Apobec1
2/2 mice. A single intravenous injection of AAV8.mLDLR was found to
significantly reduce plasma cholesterol and non-HDL cholesterol levels in chow-fed animals at doses as low as 3610
9
genome copies/mouse. Whereas Ldlr
2/2Apobec1
2/2 mice fed a western-type diet and injected with a control AAV8.null
vector experienced a further 65% progression in atherosclerosis over 2 months compared with baseline mice, Ldlr
2/2
Apobec1
2/2 mice treated with AAV8.mLDLR realized an 87% regression of atherosclerotic lesions after 3 months compared
to baseline mice. Immunohistochemical analyses revealed a substantial remodeling of atherosclerotic lesions.
Conclusions/Significance: Collectively, the results presented herein suggest that AAV8-based gene therapy for FH may be
feasible and support further development of this approach. The pre-clinical data from these studies will enable for the
effective translation of gene therapy into the clinic for treatment of FH.
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Introduction
Familial hypercholesterolemia (FH) is a life-threatening genetic
disease caused by mutations in the LDL receptor (LDLR) gene [1].
Patients with loss-of-function mutations in both LDLR alleles
(homozygous FH – hoFH) develop atherosclerosis before age 20
and, if not treated, rarely survive past age 30. Patients with hoFH
are minimally responsive to conventional LDL-lowering pharma-
cologic therapy. Orthotopic liver transplantation has been
demonstrated to substantially reduce LDL-cholesterol (LDL-C)
in hoFH patients, but obvious disadvantages and risks are
associated with this approach [2,3]. The current standard of care
in hoFH is LDL apheresis, a physical method of purging the
plasma of LDL-C which can transiently reduce LDL-C by more
than 50% [4,5,6]. However, there is re-accumulation of LDL-C in
plasma [7], and therefore apheresis has to be repeated every one to
two weeks. Anecdotal evidence suggests that this procedure may
delay the onset of atherosclerosis [8]; nonetheless it is laborious,
expensive, and not readily available. Furthermore, although the
procedure is generally well tolerated, the fact that it needs frequent
repetition and IV access can be challenging for many patients and
associated with morbidity. Therefore, there is a tremendous unmet
medical need for new therapies for hoFH.
Liver-directed gene therapy has been tested as a possible
alternative therapy for liver metabolic diseases such as hoFH.
Initial attempts to treat FH with gene therapy utilized an ex vivo
approach wherein autologous hepatocytes transduced with
retroviruses containing LDLR cDNA were transplanted into
homozygous FH patients [9]. Although this approach was well-
tolerated by patients, the impact on cholesterol metabolism was
modest and variable due in part to the limited amount of gene
transfer achievable [9,10]. More recently, attention has focused on
the potential of liver directed in vivo gene therapy for hoFH.
Nearly all in vivo gene therapy based attempts to correct FH
have used first generation adenoviral (Ad) vectors or helper-
dependent adenoviral vector systems [11,12,13,14]. While these
vectors have proven to be quite efficient, they are associated with
substantial toxicity due in part to capsid mediated activation of
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Compared to adenoviral constructs, vectors based on adeno-
associated virus (AAV) demonstrate the attractive property of long-
term expression without evidence of inflammation [15,16,17].
Initial AAV studies used AAV serotype 2 (AAV2) to express LDLR
[17]. This approach led to a transient drop in the cholesterol of
fat-fed Ldlr
2/2 mice but also triggered a transgene-specific
immune response and loss of liver-associated vector DNA;
furthermore transduction efficiency was low and efficacy was
incomplete. AAVs based on novel capsids have recently been
identified [18]; these vector candidates have shown impressive pre-
clinical data. One particular vector -AAV8- has shown great
promise in mouse and monkey models of liver directed gene
transfer, including higher transduction efficiency, less pre-existing
humoral immunity in humans, and diminished T cell responses to
the capsid [19,20,21]. AAV mediated gene transfer with these new
vectors showed long-term correction of the metabolic defect in fat-
fed Ldlr
2/2 mice [22] and prevention of atherosclerosis in
apoliporotein E deficient (ApoE
2/2) mice [19] and fat-fed
Ldlr
2/2 mice [22].
Intrinsic differences in the lipoprotein metabolism of FH animal
models used in gene therapy studies and humans, however, limit
the relevance of previous preclinical studies to the potential for
human application. In humans, the liver synthesizes solely the full-
length form of apolioprotein B (APOB), called APOB100, which
contains in its carboxy terminal region the motif mediating
binding to LDLR. However, mice express in liver high levels of the
APOB mRNA editing catalytic polypeptide-1 (APOBEC1), which
results in editing of the ApoB RNA transcript and the production of
a truncated form of the APOB protein called APOB48, which does
not bind to LDLR. Mice deleted in the Apobec1 gene synthesize
only APOB100 protein in the liver and thus more closely resemble
human physiology. Ldlr
2/2Apobec1
2/2 mice much more closely
simulate the metabolic and clinical aspects of FH than do Ldlr
2/2
mice [23]. On a chow diet, these mice develop spontaneous and
substantial hypercholesterolemia with a lipoprotein profile similar
to that of human hoFH patients. Furthermore, in contrast to
Ldlr
2/2 mice which require a high-fat diet to develop atheroscle-
rosis and develop relatively simple macrophage-rich atheroscle-
rotic lesions, Ldlr
2/2Apobec1
2/2 mice fed a chow diet develop
extensive atherosclerosis throughout the aorta, including most of
the branch points; these lesions range in morphology from simple
lesions of macrophage foam cells to more complex lesions
containing smooth muscle cells and extracellular matrix [24].
Feeding a high-fat diet to Ldlr
2/2Apobec1
2/2 mice further
enhances the rate of progression of atherosclerosis [23]. To date,
no gene therapy studies have evaluated FH correction in this
mouse model.
For in vivo gene therapy of FH to become a clinical reality, pre-
clinical studies need to be conducted using the proper combination
of vector, transgene, and animal model that accurately reflects FH
pathophysiology. The advent of AAV8 and the availability of
Ldlr
2/2Apobec1
2/2 mice provide an opportunity to critically
evaluate the potential of gene therapy for hoFH using current
models and gene transfer technology.
Materials and Methods
Animals
Male C57BL/6 Ldlr
2/2Apobec1
2/2 mice were bred in house
and have been described elsewhere [23]. For expression and
efficacy studies, mice were given unrestricted access to water and
were fed a standard chow diet. The vector was injected via an
intravenous tail-vein injection with specified genome copies (gc)/
mouse. Animals were sacrificed 35 days after gene transfer. For all
studies, blood was obtained at least one times before and at
designated time-points after gene transfer. For atherosclerosis
regression studies, three groups of male mice (n=10 per group)
were given unrestricted access to water and were fed a high-fat
western diet (0.15% cholesterol, 21% butterfat; DYETS, PA,
USA) starting 8 weeks prior to vector injection and maintained on
this diet throughout the experiment. After 8 weeks on the high-fat
diet, prior to vector injection, one group of mice (baseline) was
sacrificed for various analyses. The second and third groups
were injected with 1610
11 GC of AAV8.TBG.mLDLR or
AAV8.TBG.nLacZ vector, respectively. Eight weeks after vector
treatment, mice were sacrificed for the indicated analyses.
Ldlr
2/2Apobec1
2/2ApoB
+/+ mice were generated by crossing
Ldlr
2/2Apobec1
2/2 [23] with human ApoB transgenic mice [25].
Ldlr
2/2Apobec1
2/2ApoB
+/+ mice are viable, fertile, and do not
display any gross physical or behavioral abnormalities. These
animals were bred in house and maintained on a chow diet. All
study protocols were approved by the Institutional Animal Care
and Use Committee at The University of Pennsylvania (Protocol
Approval #800791).
Cloning and AAV Production
The mouse Vldlr and Ldlr AAV constructs were cloned in an
AAV ITR flanked construct named pENN AAV TBG PI
construct which drives expression from a thyroxine-binding
globulin (TBG) hepatocyte specific promoter with a chimeric
intron from Promega Corporation (Madison, Wisconsin) encoding
the 59-donor site from the first intron of the human b-globin and
the branch and 39-acceptor site from the intron located between
the leader and body of an immunoglobulin gene heavy chain
variable region. The cDNA sequences were amplified from PCR
from constructs acquired from openbiosystems.com (Ldlr: genbank
accession number BC019207; Vldlr: BC013622) with primers:
MLU-mLDLR F (gtaagcACGCGTaagctaaggatgagcaccgcgga-
tctgat),
MLU-mLDLR R (TTGAttcACGCGTtcatgccacatcgtcctccagg-
ctgaccatc),
MLU-mVLDLR F (gtaagcACGCGTgcgggcagcatgggcacgtccg-
cgcgctgg),
SAL-mVLDLR R (ggaatcGTCGACtcaagccagatcatcatctgtgctta-
caac).
The Vldlr construct was generated by MluI-SalI insertion of the
cDNA insert into pENN AAV TBG PI construct. Ldlr was cloned
by MluI insertion of the cDNA amplicon into the same AAV
construct. AAV vector was generated by triple transfection of the
AAV ITR flanked construct with the packaging plasmid pAAV2/
8 and the helper plasmid pdF6 as previously described [20,21].
AAV vector particles were purified by double CsCl gradient
banding as described in Wang et al [21].
En Face Quantification of Atherosclerotic Lesions in the
Aorta
Mice were anesthetized, the aorta was gently perfused with
saline via the left ventricle, and the heart was cut off at the base
and embedded in OCT. The rest of the aorta was removed and
fixed in 10% formalin/PBS for at least 3 days. Aortic arch lesion
area was quantitated using a method similar to that previously
described [26,27]. After the adventitial and adipose tissue was
removed, the aortic arches were stained with oil red O solution
(1.8% oil red O, wt/vol, in 60% isopropanol, filtered twice
through a 0.2-mm filter) for 15 minutes and destained with 60%
isopropanol for 5 minutes to eliminate background staining. The
outer curvature of the arch was cut longitudinally, and the arch
Lipoprotein Metabolism
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(BioGenex). The image was captured with the use of a Leica
MZIZ microscope and digitized, and the oil red O–stained lesion
area was quantitated using the Image J image analysis system. All
data capture and quantitation were performed in a blinded
fashion.
Immunohistochemistry and Quantification of
Atherosclerosis Lesions in the Aortic Root
LDLR expression in liver was detected on frozen sections that
were fixed in acetone (220C) for 5 min, air dried, blocked with
1% goat serum in PBS for 20 min, and incubated for 1 h with a
rabbit serum against LDLR (a gift from Dr. William Lagor and
Dr. Gene C. Ness) diluted 1:200 in blocking buffer [28]. After
washing in PBS, the sections were treated for 30 min with FITC-
labeled secondary antibodies against rabbit IgG diluted in
blocking buffer (Vector Laboratories, 1:200) and mounted with
Vectashield containing DAPI (Vector). Fresh-frozen OCT-
embedded hearts were used for Immunohistochemistry of lesions
in the aortic root. Serial sections of the aortic root were mounted
on masked slides. Sections were fixed in acetone, air-dried, and
rehydrated in PBS containing 0.02% NaN3 and blocked with 1%
BSA in PBS/NaN3 and 1% goat serum. For lesion analysis,
sections were stained with oil-red-o or hematoxylin and eosin.
Images were captured digitally with a video camera connected to
a Leica microscope. The digitized images were analyzed with
Image J image analysis software. Total lesion area was quantified
by manual tracing of entire intimal lesion in 10 equally spaced
aortic root sections per mouse. The acquisition of images and
analysis of lesions were performed in a blinded fashion. For
detection of macrophages, or VCAM-1, sections were reacted
with rat antibodies against CD68 (clone FA-11, Serotec) and
VCAM-1 (clone 429, BD Pharmingen) diluted 1:200 and 1:25 in
blocking buffer, respectively. A Vectastain Elite ABC kit (Vector)
was used according to the manufacturer’s protocol to visualize
bound rat antibodies. Collagen was detected by trichrome
staining using a staining kit from Sigma following the manufac-
turer’s protocol.
Analytical Methods
The plasma total cholesterol levels were measured in individual
mice at each time point with an enzymatic assay on a Cobas Fara
II (Roche Diagnostic Systems Inc) with the use of Sigma reagents
(Sigma Chemical Co). Plasma samples from groups of 5 mice were
pooled at each time point and subjected to fast protein liquid
chromatography (FPLC) gel filtration (Pharmacia LKB Biotech-
nology) on two Superose 6 columns. Cholesterol concentrations in
the fractions were determined with an enzymatic assay (Wako
Pure Chemical Industries, Ltd). For hepatic cholesterol and
triglyceride analysis, liver was homogenized in a saline solution
(,250 mg liver/ml saline). Cholesterol and triglyceride were
measured as described [29] after solubilization of lipid by
deoxycholate using cholesterol reagent or triglyceride reagent
and lipid lintrol standards.
Statistical Analyses
Atherosclerotic lesion area data were subjected to a 1-way
ANOVA. Experimental groups were compared with the baseline
group by using the Dunnett test. Repeated-measures ANOVA was
used to compare cholesterol levels among different groups of mice
Figure 1. Evaluation of AAV8 encoding mouse Vldlr or mouse Ldlr in Ldlr-/-Apobec1-/- Mice. (A) Plasma cholesterol levels in Ldlr-/-
Apobec1-/- mice after treatment with AAV8.TBG.mVLDLR or AAV8.TBG.mLDLR (n=5 animals per dose group). Each point represents mean 6 s.d.
*P,0.05, **P,0.01, ***P,0.001 (B and C) Pooled mouse plasma from AAV-injected Ldlr-/-Apobec1-/- (n=5) were analyzed by FPLC fractionation and
the cholesterol content of each fraction was determined. (B) Lipoprotein profile of animals injected with 1610‘12 GC of vector 28 days after
treatment. (C) Lipoprotein profile of animals injected with 3610‘11 GC of vector 28 days after treatment. (D) Plasma ALT levels in Ldlr-/-Apobec1-/-
mice after treatment with AAV8.TBG.mVLDLR or AAV.TBG.mLDLR (n=5 animals per dose group). Each point represents mean 6 s.d. At all time points
and doses examined, no significant differences in ALT were detected between AAV8.TBG.mLDLR and AAV8.TBG.mVLDLR.
doi:10.1371/journal.pone.0013424.g001
Lipoprotein Metabolism
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comparisons was assigned at P,0.05. Graphs represent mean6
SD values.
Results
mLDLR is more effective than mVLDLR in correcting
hypercholesterolemia
Although LDLR is the logical transgene to use for gene therapy
of FH, we and others have considered an alternative approach
using the gene encoding the very-low-density lipoprotein receptor
(VLDLR) which is a member of the LDLR super family that binds
with high affinity to APOE containing lipoproteins such as VLDL
[14,17]. While this gene is not expressed in liver, vector mediated
gene transfer of VLDLR to liver does partially ameliorate
hypercholesterolemia in rabbits [13] and mice deficient in Ldlr
[12,13,17]. One advantage of VLDLR is that it should be viewed
as a self protein in hoFH patients and therefore should not elicit
adaptive immune responses [12,17].
A proximal step in the development of a clinical trial of gene
therapy for hoFH is the selection of the transgene which, in the
case of hoFH, could be LDLR or VLDLR. We performed a direct
comparison of AAV8 mediated gene transfer of the murine
versions of both genes at three doses (1610
12,3 610
11 and 1610
11
GC/mouse) in chow-fed Ldlr
2/2Apobec1
2/2 mice using a liver
specific promoter, thyroxine binding globulin (TBG). Within seven
days of vector administration, a marked reduction in plasma
cholesterol was realized in Ldlr
2/2Apobec1
2/2 mice injected with
AAV8.TBG.mLDLR at all doses compared to control
AAV8.TBG.nLacZ treated animals, in which serum lipids were
maintained at the high baseline levels throughout the study
(Fig. 1A). In the low-dose (1610
11 GC/mouse) group, for
example, plasma cholesterol levels significantly fell from a baseline
level of 505659 mg/dl to 112634 mg/dl. AAV8.TBG.mVLDLR
treated animals realized much less significant decreases in levels of
total plasma cholesterol (Fig. 1A). We also examined FPLC
fraction cholesterol levels 28 days after treatment with the high
and (Fig. 1B) and intermediate-dose of vector (Fig. 1C).
AAV8.TBG.mLDLR at both doses was considerably more effective
than AAV8.TBG.mVLDLR in reducing levels of VLDL and IDL/
LDL in Ldlr
2/2Apobec1
2/2 mice; in contrast, a prominent IDL/
LDL peak was detected at both doses of AAV8.TBG.mVLDLR
Figure 2. Evaluation of the minimum effective dose of AAV.TBG.mLDLR vector in Ldlr-/-Apobec1-/- Mice. Amounts of (A) Plasma
cholesterol and (B) non-HDL cholesterol were evaluated in Ldlr-/-Apobec1-/- mice up to day 35 after treatment with different doses of AAV8.mLDLR
(n=9 animals per dose group). Each point represents mean 6 s.d. *P,0.05, **P,0.01, ***P,0.001. (C) Pooled mouse plasma from AAV-injected
Ldlr-/-Apobec1-/- (n=5, per dose group) were analyzed by FPLC fractionation and the cholesterol content of each fraction was determined. (D) Dose
response analysis of Day 60 samples examining cholesterol levels as a function of vector dose. (E) Plasma cholesterol and (F) Alanine transaminase
were evaluated in Ldlr-/-Apobec1-/- mice up to day 180 days after treatment with 1610‘11 GC of AAV8.TBG.mLDLR (n=10) or 1610‘11 GC of
AAV8.TBG.nLacZ (n=9). Each point represents mean 6 s.d.
doi:10.1371/journal.pone.0013424.g002
Lipoprotein Metabolism
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group (Fig. 1D). Given these results, the remaining experiments
focused exclusively on characterizing AAV8.TBG.mLDLR func-
tion in vivo.
AAV8 mediated gene transfer of mLDLR is effective at
low doses of vector
Critical to the success of gene therapy is the demonstration of
efficacy at doses of vector that are safe and can be easily
manufactured. Formal regulatory review of a proposed human
study requires an assessment of the minimal dose that shows some
metabolic/clinical effect [30]. Chow-fed male Ldlr
2/2Apobec1
2/2
mice were treated with a single intravenous injection of
AAV8.TBG.mLDLR; doses ranged from 1610
12 genome cop-
ies/mouse to 3610
8 genome copies (GC)/mouse. Thirty-five days
after vector injection, mice were necropsied and livers were
harvested and processed for presence and abundance of vector
genomes and LDLR protein [21].
Correction of hypercholesterolemia was found to be dose
dependent. With respect to total cholesterol (Fig. 2A) and non-
HDL cholesterol (Fig. 2B), reduction was realized within seven
days of vector treatment. The most significant decreases were
observed at the highest treatment doses. Surprisingly, reduction
was observed with doses as low as 3610
9 GC/mouse with total
cholesterol levels dropping 35% from 397626 mg/dl at baseline
to 256629 mg/dl on day 35 and non-HDL cholesterol levels
decreasing by 45% from 284619 mg/dl at baseline to
154617 mg/dl (Fig. 2B) on day 35. This magnitude of correction
is comparable to that seen in Ldlr
2/2Apobec1
2/2 mice treated with
1610
11 GC/mouse of AAV8.TBG.mVLDLR (Fig. 1A), suggesting
that AAV8.TBG.mLDLR is at least 30 fold more effective than
AAV8.TBG.mVLDLR. With respect to FPLC fraction cholesterol
levels, all doses of AAV8.TBG.mLDLR, except 3610
8 GC, led to
substantial reductions in the IDL/LDL peak compared to
AAV8.TBG.nLacZ treated Ldlr
2/2Apobec1
2/2 mice. Only the
higher doses of 1610
11 GC/mouse and 1610
10 GC/mouse also
reduced the HDL-C levels compared to control Ldlr
2/2Apobec1
2/
Figure 3. Efficacy of vector mediated transgene expression in liver. (A) Vector DNA expression in the liver. The amount of vector
genomes in the liver Ldlr-/-Apobec1-/- mice (n=9 mice per group) was assessed by Taqman analysis of total genomic DNA harvested at day 35 after
vector administration. The limit of detection is 10 genome copies/mg DNA. (B) Membrane fraction of liver extract at day 35 was prepared from AAV-
treated Ldlr-/-Apobec1-/- mice and subjected to Western blot analysis for the detection of transgene expression using LDLR specific antiserum.
Positive control is liver extracts from B6 mice. Negative control is liver extracts from AAV8.TBG.nLacZ treated Ldlr-/-Apobec1-/- mice. (C) Histological
analysis of mouse liver. Immunofluorescence staining was performed on mouse liver sections for detection of LDLR expression in Ldlr-/-Apobec1-/-
mouse at day 35 after vector administration. Cryo-preserved liver section were prepared and probed with rabbit serum against LDLR followed by FITC
labeled secondary antibody. Total levels of cholesterol (D) and (E) triglycerides were measured in the livers of Ldlr-/-Apobec1-/- mice at day 35. No
significant differences were detected between any of the treatment groups (n=5 mice per treatment group).
doi:10.1371/journal.pone.0013424.g003
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data revealed a clear dose-dependent response with regard to
reduction of total cholesterol levels (Fig. 2D). Long-term studies
revealed that treatment of Ldlr
2/2Apobec1
2/2 mice with 1610
11
GC AAV8.TBG.mLDLR resulted in significant correction of
cholesterol (Fig. 2E) in the absence of ALT elevation for up to 6
months after injection of vector (Fig. 2F). Collectively, these data
reveal that 1610
10 GC/mouse is the minimum effective dose
required for complete correction; furthermore, partial correction
can be attained with as little as 3610
9 GC/mouse. Importantly,
this correction was maintained for up to 6 months after treatment
with no detectable inflammation.
Taqman analysis revealed a dose dependent recovery of vector
genomes from the liver (Fig. 3A). Using Western blot analysis,
we detected LDLR immunoreactive protein in the liver of
AAV8.TBG.mLDLR treated mice with vector doses equal to or
greater than 1610
10 GC (Fig. 3B). At 1610
10 GC/mouse, only the
mature form of the LDLR protein (160 kDa band) was detected,
whereas in the higher dose groups, both the mature and immature
incompletely glycosylated forms (120 kDa band) were present
[31]. Immunofluroesence analysis revealed dose dependent
expression of immunoreactive LDLR in liver (Fig. 3C); specifically,
within 35 days of vector treatment, 60 to 70% of hepatocytes
expressed immunoreactive LDLR following injection with 1610
12
GC/mouse whereas between 5 to 10% of hepatocytes expressed
detectable LDLR at the lowest dose showing some metabolic
improvement (i.e., 3610
9 GC/mouse). As expected, no LDLR
protein was observed in the livers of AAV8.TBG.nLacZ treated
Ldlr
2/2Apobec1
2/2mice (Fig. 3B and 3C). Importantly, over-
expression of mLDLR did not result in the pathologic accumulation
of hepatic cholesterol (Fig. 3D) or hepatic triglycerides (Fig. 3E) at
any of the doses examined.
AAV8.mLDLR Induces marked regression of
atherosclerosis
Given that AAV8.TBG.mLDLR markedly lowered total choles-
terol and non-HDL cholesterol, we next examined whether
AAV8.TBG.mLDLR had any effect on the progression or even
the regression of atherosclerotic lesions. Three groups of male
Ldlr
2/2Apobec1
2/2 mice were fed a high-fat western-type diet to
hasten the progression of atherosclerosis. After two months of the
atherogenic diet, one group of mice received a single intravenous
injection of 1610
11 GC/mouse of control AAV8.TBG.nLacZ
vector, one group received 1610
11 GC/mouse of AAV8.
TBG.mLDLR vector, while a third baseline group of animals was
necropsied for atherosclerosis lesion quantification. The mice who
received vectors were maintained on the high-fat diet for an
additional 60 days at which time they were necropsied. Animals
that received the AAV8.TBG.mLDLR vector realized a rapid drop
in total cholesterol from 15556343 mg/dl at baseline to 266678
at day 7 and to 67613 by day 60 after treatment (Fig. 4A). By
contrast, the plasma cholesterol levels of AAV8.TBG.nLacZ
treated mice remained virtually unchanged from 15666276 at
baseline to 1527667 when measured 60 days after vector (Fig. 4A).
The same trend was observed with respect to non-HDL
cholesterol (Fig. 4B). All animals developed slight increases in
serum transaminanses following the 2 months on the high fat diet,
which remained elevated following treatment with the
AAV8.TBG.nLacZ vector but diminished three-fold to normal
levels after treatment with the AAV8.TBG.mLDLR vector
(Fig. 4C).
Evolution of pre-existing atherosclerotic lesions was assessed by
two independent methods.In the first method the aortas were opened
from the arch to the iliac bifurication and stained with Oil Red O
(Fig. 5A); morphometric analyses quantified the percent of aorta
Figure 4. Evaluation of AAV8.TBG.mLDLR vector in high fat fed Ldlr-/-Apobec1-/- mice. Amounts of (A) Plasma cholesterol (B) non-HDL
cholesterol, and (C) Alanine transaminase were evaluated in Ldlr-/-Apobec1-/- mice up to day 60 after treatment with 1x10‘11 GC of AAV8.TBG.mLDLR
(n=10) or 161011 GC of AAV8.TBG.nLacZ (n=9). Each point represents mean 6 s.d. *P,0.05, { P,0.001.
doi:10.1371/journal.pone.0013424.g004
Lipoprotein Metabolism
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13424stained with Oil Red O along the entire length of the aorta (Fig. 5B).
Two months of high fat diet resulted in extensive atherosclerosis
covering 20%ofthe aorta reflectingthebaseline disease atthetimeof
vector; this increased to 33% over an additional two month period
following treatment with the AAV8.TBG.nLacZ vector, representing
a 65% further progression in atherosclerosis. In contrast, treatment
with the AAV8.TBG.mLDLR vector led to a regression of
atherosclerosis by 87% over two months, from 20% of the aorta
covered by atherosclerosis at baseline to only 2.6% of the aorta
covered by atherosclerosis 60 days after vector administration.
In the second method, total lesion area was quantified in the
aortic root (Fig. 5C–5F). This analysis revealed the same overall
trends, with AAV8.TBG.nLacZ injected mice showing a 44%
progression over 2 months compared to baseline mice, while
AAV8.TBG.mLDLR injected mice demonstrating a 64% regres-
sion in lesion compared with baseline mice. In summary,
expression of LDLR via injection of AAV8.TBG.mLDLR induced
marked reduction in cholesterol and substantial regression of
atherosclerosis over 2 months as assessed by 2 independent
methods of quantification at 2 different sites within the aorta.
For further assessment of lesion remodeling, immunostaining
was performed on fresh-frozen sections of the aortic root.
Samples were examined for CD68, a foam cell marker (Fig. 6A),
VCAM-1, an adhesion molecule that plays a role in atheroscle-
rotic lesion formation (Fig. 6B), and collagen, a molecule that
determines the mechanical stability of atherosclerotic plaques
(Fig. 6C). Lesions in baseline treated groups were advanced, with
many necrotic centers, CD68+ macrophages and macrophage-
derived foam cells, and extensive VCAM-1 and collagen in the
expanded neointima (Fig. 5F and 6A–6C) These results
demonstrate the complexity of the lesions in the pre-injected
aorta (i.e., that they had progressed past the early macrophage
foam cell stage). AAV8.TBG.nLacZ treated animals displayed
similar advanced pathology. In contrast, AAV8.TBG.mLDLR
treated mice had much smaller lesions with decreased areas of
CD68, VCAM-1, and collagen immunostaining in the intima and
media. These results indicate a change in smooth muscle cell
phenotype that is part of the wide-scale remodeling process that
occurred during the 2 months in which systemic lipid levels where
normalized.
Figure 5. AAV8.TBG.mLDLR mediated regression of atherosclerotic lesions in high-fat fed Ldlr-/-Apobec1-/-mice. (A) En face Sudan IV
staining. Mouse aortas were pinned and stained with Sudan IV, which stains neutral lipids. Representative aortas from animals treated with 1610‘11
of AAV8.TBG.nLacZ, 1610‘11 of AAV8.TBG.mLDLR at day 60 after vector administration (day 120 on high-fat diet), or at baseline (day 60 on high-fat
diet) are shown. (B) The percent Sudan IV staining of the total aortic surface in baseline (n=10), AAV.TBG.nLacZ (n=9) and AAV8.TBG.mLDLR (n=10)
was determined as described under Materials and Methods. Aortic roots from these mice were stained with oil red o (C) or hematoxylin and eosin
(H&E) (D) 106 magnification. Quantification was conducted on oil red o lesions (E) as described in the materials and methods. Each column
represents mean 6 s.d. *P,0.05, **P,0.01, ***P,0.001, { P,0.001. (F) H&E stained aortic roots at 406magnification show a thin fibrous cap and
expanded necrotic core in lesions of baseline and AAV8.nLacZ treated mice compared to AAV8.mLDLR injected animals.
doi:10.1371/journal.pone.0013424.g005
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Homozygous FH emerged as a model for liver-directed gene
therapy in the 1980s with the demonstration of metabolic
correction in patients following liver transplantation and genetic
correction of deficient hepatocytes ex vivo with retroviruses[9,10].
The optimal approach is in vivo targeting of hepatocytes following
systemic delivery of vector, which is facilitated by the presence of
fenestrae in liver capillaries[32]. Genotype/phenotype studies in
patients with hoFH indicated the potential for efficacy in those
with complete deficiency of LDLR following less than complete
genetic reconstitution from gene therapy [9,10,33]. Finally, a
simple measurement of serum lipids provides a specific, sensitive
and relevant read out of gene transfer and clinical efficacy.
One of the biggest challenges in evaluating a novel gene therapy
approach for the clinic is the identification of an authentic animal
model for assessing efficacy and safety. This is particularly
important when the underlying pathology of the disease may
impact on vector performance as may be the case for the steatosis
of liver in hoFH [34]. Animal models of hoFH have been
described in rabbits and monkeys although they suffer from some
significant limitations in terms of biology, genetics, available
reagents and accessibility [35,36,37]. The mouse provides some
substantial advantages especially as it relates to germ line
engineering to render animal more ‘‘human like’’ as was the case
with the mouse models used in this study.
Studies with AAV8 expressing mLDLR in the Ldlr
2/2
Apobec1
2/2 mouse showed impressive efficacy. Reductions in
serum cholesterol of 35%, which according to human phenotype/
genotype studies should be beneficial [33], were achieved with
3610
9 GC/mouse. This dose translates to 3610
12 GC for a 20 kg
adolescent and 1610
13 GC for a 70 kg adult which is well within
the reach of current manufacturing protocols [38]. Most
importantly, we show that complete amelioration of hypercholes-
terolemia led to marked regression of atherosclerosis over two
months despite continuation of the western-type diet. This result
represents the fastest and most substantial regression of athero-
sclerosis seen in a murine model after reduction in plasma
cholesterol.
A formal evaluation of safety awaits GLP toxicology studies,
although our data to date demonstrated no toxicity up to 10
12 GC.
In fact, normalization of cholesterol following gene therapy
actually improved the hepatotoxicity associated with steatosis that
occurred when the animals were on a high fat diet (Fig. 4C).
Recent reports suggest that the constitutive over-expression of
LDLR may lead to pathological accumulation of lipids and
cholesterol in hepatocytes and that the use of physiologically
controlled expression elements is required for the design of FH
gene therapy [39,40]. This effect has been seen in vitro and in vivo
following delivery of LDLR expression plasmids under the control
of strong viral promoters [39,40]. No such pathologies (Fig. 3D–
3E) were observed in our studies highlighting the importance of
Figure 6. Immunohistochemical analysis of mouse atherosclerotic lesions. Representative aortic root sections immunostained for the foam
cell marker CD68 (A), VCAM-1 (B), or Masson trichrome blue stain for collagen content (C). Original magnification, 406. Note abundant
immunostaining for foam cell marker, CD68 (brown), VCAM-1 adhesion molecules (also brown), and presence of collagen ablue) within lesion in
baseline and AAV.TBG.nLacZ injected Ldlr-/-Apobec1-/-animals.
doi:10.1371/journal.pone.0013424.g006
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designing gene therapy strategies.
Several additional aspects of AAV biology should be considered
in possible clinical trials. We have shown that even low levels of
pre-existing neutralizing antibodies (NAB) due to natural AAV
infections will diminish gene transfer and potentially change vector
bio-distribution[41]. AAV8 was isolated from a rhesus macaque
and NABs to it are lower in humans than what is present to
presumably human derived AAVs like AAV2 [18,42]. However,
some humans do show low levels of NAB to AAV8 [43]. Mouse
studies like the ones described in this paper demonstrate the
remarkable result of tolerance to antigenic transgenes [44]
although our primate [45] and canine studies [20,46] indicate
that the threshold for T cell tolerance is lower in larger animals
and presumably humans. Based on these findings we suggest that
initial clinical trials be restricted to hoFH subjects who 1) are
AAV8 NAB negative and 2) have at least one allele that expresses
LDLR protein that spans most of its open reading frame to
promote deletion of T cells to wild type LDLR. A final concern
relates to the activation of T cells to capsids and killing of
transduced hepatocytes which is a hypothesis that emerged from
an AAV2 clinical trial in hemophilia [47,48]. It seems prudent to
consider a similar biology may occur with other AAV serotypes
although our studies indicate this is unlikely to happen with AAV8
as it lacks the necessary dendritic cell interactions to effect cross
presentation of capsids [49,50].
In summary, our results suggest that the intravenous injection in
mice of a low dose of an AAV8-based vector encoding the LDLR
cDNA generates sustained expression of the LDLR protein in the
liver without evidence of hepatic inflammation or toxicity and is
highly effective in markedly reducing plasma cholesterol levels and
regressing atherosclerosis in a ‘‘humanized’’ murine model of
hoFH. These results suggest that AAV8-based gene therapy for
hoFH may be feasible and support further development of this
approach.
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